Hong Kong Interactive Media and Services Stock News

Huishang Bank (SEHK:3698) has drawn fresh attention after reporting its full year 2025 earnings. The bank recorded net income of CN¥16,524.6 million and earnings per share of CN¥1.14 from continuing operations. See our latest analysis for Huishang Bank. The full year 2025 earnings release and the recent board meeting around the dividend appear to have coincided with stronger sentiment, with Huishang Bank’s 90 day share price return of 43.75% and 1 year total shareholder return of 85.38%...

Anton Oilfield Services Group (SEHK:3337) closed FY 2025 with fourth quarter revenue of C¥1.9b and net income of C¥143.2m, while trailing twelve month revenue came in at C¥5.6b with net income of C¥373.1m and EPS of C¥0.137. Over recent periods the company has seen quarterly revenue move from C¥1.1b in the third quarter of 2024 to C¥1.3b in the second quarter of 2025 and then to C¥1.9b in the fourth quarter of 2025. Over the same stretch, net income has ranged from C¥52.9m to C¥143.2m, with...

InSilico Medicine Cayman TopCo (SEHK:3696) has opened FY 2025 with first half revenue of US$27.5 million and a basic EPS loss of US$0.25, while trailing twelve month figures show revenue of US$56.2 million alongside a net loss of US$352.3 million and EPS of US$4.48 in the red. Over the recent reported periods, the company has seen revenue shift from US$59.7 million in the first half of FY 2024 to US$26.1 million in the second half and then to US$27.5 million in the first half of FY 2025. Net...

Star Shine Holdings Group (SEHK:1440) has put investors on alert with fresh guidance pointing to a larger FY2025 net loss, just ahead of its March 30 results announcement and the related board meeting. See our latest analysis for Star Shine Holdings Group. The earnings warning has shifted sentiment sharply in the short term, with a 10.83% 1 day share price return decline and a 6.38% 7 day pullback, despite a strong 90 day share price return of 89.75% and a very large 5 year total shareholder...

China Resources Pharmaceutical Group (SEHK:3320) has come into focus after reporting full year 2025 results and hosting its earnings call, alongside a Board proposal to lift the final cash dividend compared with 2024. See our latest analysis for China Resources Pharmaceutical Group. The earnings release and higher proposed dividend appear to have coincided with a sharp improvement in sentiment, with a 7 day share price return of 28.67% and a 30 day share price return of 25.27% helping lift...

Hansoh Pharmaceutical Group (SEHK:3692) just posted its FY 2025 first half results with revenue of C¥7.4b and basic EPS of C¥0.53, against a trailing twelve month backdrop of C¥15.0b in revenue and C¥0.93 in EPS off C¥5.6b in net income, as well as earnings growth of 27.1% over the past year. The company has seen revenue move from C¥6.5b and EPS of C¥0.46 in 1H FY 2024 to C¥5.8b and EPS of C¥0.28 in 2H FY 2024, and now to C¥7.4b and EPS of C¥0.53 in 1H FY 2025. This sets up a story where rich...

Kindstar Globalgene Technology (SEHK:9960) has reported its FY 2025 first half results with revenue of C¥456.9 million and a basic EPS loss of C¥0.0378, while trailing 12 month figures show revenue of C¥933.6 million and a basic EPS loss of C¥0.0592. Over the past three half year periods, revenue has moved from C¥473.3 million in 1H 2024 to C¥454.2 million in 2H 2024 and C¥456.9 million in 1H 2025, alongside a shift in basic EPS from C¥0.0125 to a loss of C¥0.0706 and then a smaller loss of...

Fosun International share performance snapshot Fosun International (SEHK:656) has drawn investor attention after recent share price moves, with the stock showing a 2.2% decline over the past day but gains over the past week and month. See our latest analysis for Fosun International. That 2.2% one-day share price decline comes after a 9.5% seven-day share price return and a weaker one-year total shareholder return of a 2.7% decline, which suggests recent momentum contrasts with longer-term...

Jiangsu Expressway (SEHK:177) has wrapped up FY 2025 with fourth quarter revenue of C¥7.3b and basic EPS of C¥0.15, alongside trailing twelve month revenue of C¥20.3b and EPS of C¥0.91 that sit against an improved net margin of 22.6% compared with 21.3% a year earlier. Over recent periods, revenue has ranged from C¥3.6b to C¥9.1b per quarter while quarterly EPS has moved between C¥0.15 and C¥0.28, giving investors a clear view of how earnings track the top line across the year. With that...

What China XLX Fertiliser’s latest earnings mean for investors China XLX Fertiliser (SEHK:1866) just released its 2025 annual results, pairing modest profit growth after non recurring items with a 23.1% dividend increase, an improved borrowing mix, and ongoing expansion of new production bases. See our latest analysis for China XLX Fertiliser. The earnings release has arrived alongside a sharp 9.5% 1 day share price return, adding to a 90 day share price return of 28.2% and a very large 1...

PetroChina (SEHK:857) has laid out a steady set of FY 2025 numbers, with fourth quarter revenue at C¥695.2b and basic EPS of C¥0.17, while trailing twelve month revenue stands at C¥2.86t and EPS at C¥0.86. Over recent periods the company has seen quarterly revenue move between C¥681.7b and C¥753.1b and basic EPS range from C¥0.17 to C¥0.26. This gives you a clear view of how the top line and per share earnings have tracked into the latest print. With a trailing net profit margin near the mid...

Zhongyu Energy Holdings (SEHK:3633) opened FY 2025 with first half revenue of about HK$6.6b and basic EPS of HK$0.089, setting a cleaner profit picture against a share price of HK$2.68. The company reported revenue of roughly HK$7.3b in 1H 2024 and HK$6.6b in 1H 2025, while basic EPS moved from HK$0.086 in 1H 2024 to HK$0.089 in the latest period. This leaves investors with a results set where modest EPS progress sits alongside a relatively slim earnings margin profile. See our full analysis...

Goodbaby International Holdings (SEHK:1086) FY 2025 earnings snapshot Goodbaby International Holdings (SEHK:1086) has released its FY 2025 numbers with first half revenue of HK$4.3b and basic EPS of HK$0.06. This provides context for how you might weigh the latest results against the share price of HK$0.99. Over recent periods, the company has reported revenue between HK$4.2b and HK$4.6b per half, while basic EPS ranged from HK$0.11 to HK$0.06, giving a clear view of how the top line and per...

Xinte Energy (SEHK:1799) has reported FY 2025 first half revenue of C¥7.3b with a basic EPS loss of C¥0.18, while trailing twelve month revenue sits at C¥15.3b against a basic EPS loss of C¥0.84. Over recent periods, the company has seen revenue move from C¥11.7b in 1H 2024 to C¥9.5b in 2H 2024 before landing at C¥7.3b in 1H 2025, with basic EPS losses of C¥0.62, C¥2.11 and C¥0.18 respectively. Investors are likely to focus on how these headline numbers compare with expectations around...

Jinshang Bank (SEHK:2558) has put fresh numbers on the table for FY 2025, with first half revenue of C¥1.96b and basic EPS of C¥0.18 setting the tone for how the rest of the year may be judged. Over recent periods the bank has seen revenue move between C¥1.96b and C¥2.16b per half year, while basic EPS has ranged from C¥0.12 to C¥0.18. This gives you a clear view of how the income line and per share earnings have been tracking into this latest report. With a net profit margin in the low 40s...

China Risun Group (SEHK:1907) has reported FY 2025 first half revenue of C¥20.5b and basic EPS of C¥0.0066, with the latest twelve month figures showing revenue of C¥39.3b and basic EPS of C¥0.013. The company has seen revenue move from C¥25.2b in the first half of 2024 to C¥22.3b in the second half of 2024 and then to C¥20.5b in the first half of 2025. Over the same periods, basic EPS shifted from C¥0.025383 to a loss of C¥0.021219 and then to C¥0.0066, setting up an earnings story that now...

Event context and recent share performance Ascentage Pharma Group International (SEHK:6855) has attracted investor attention recently, with the share price moving 7.5% over the past week and 7.5% over the past month, against a small decline in the past 3 months. Over a longer horizon, the stock shows a negative year to date return, alongside a 6.9% 1 year total return. This gives investors a mixed backdrop to assess the company’s clinical stage biotech profile and current valuation...

Innovent Biologics (SEHK:1801) has drawn investor attention after recent share price moves, with the stock up 7.7% over the past day and 5.5% over the past week, inviting a closer look at its current valuation. See our latest analysis for Innovent Biologics. That 7.7% 1 day share price return and 8.5% year to date share price return sit against a 1 year total shareholder return of 85.1% and a 3 year total shareholder return of 143.2%, suggesting momentum has been building over time as the...

AIA Group (SEHK:1299) has drawn investor attention after recent share price moves, with the stock showing mixed returns over the past month and past 3 months, alongside reported revenue of $26,215m and net income of $6,234m. See our latest analysis for AIA Group. Over the past year, AIA Group’s share price return has been more muted than its 47.66% total shareholder return. This suggests dividends and other distributions have played a meaningful role even as recent short-term share price...

AsiaInfo Technologies Limited's ( HKG:1675 ) earnings announcement last week didn't impress shareholders. Despite the...

As you might know, Jiumaojiu International Holdings Limited ( HKG:9922 ) last week released its latest annual, and...

NagaCorp Ltd. recently reported full-year 2025 results, with revenue of US$709.67 million and net income of US$309.91 million, and proposed a final dividend of US$0.0109 per share subject to shareholder approval on 25 June 2026. The combination of higher earnings per share of US$0.0701 and a new final dividend proposal signals management’s confidence in the company’s financial position. With these results and the proposed final dividend under consideration, we’ll explore how this payout...

China Conch Venture Holdings (SEHK:586) has come into focus after releasing its full year 2025 results, reporting sales of CN¥6,547.71 million and net income of CN¥2,245.14 million, alongside higher basic earnings per share. See our latest analysis for China Conch Venture Holdings. The latest full year earnings release has arrived alongside a shifting share price picture, with the stock at HK$11.95 after a 1 day share price return of 2.14% and a 7 day share price return of 8.64%. While the 90...

Why Simcere’s latest earnings and cancer trial update matter for investors Simcere Pharmaceutical Group (SEHK:2096) has just paired strong full year 2025 earnings with encouraging Phase I/II data for its bladder cancer therapy SIM0237, a combination that is drawing fresh attention from investors. See our latest analysis for Simcere Pharmaceutical Group. The latest 7.96% 1 day share price return to HK$12.07, alongside a 52.80% 1 year total shareholder return and solid multi year gains, points...